Dr. Coler has focused on four main multi-disciplinary areas: 1) Advancing tuberculosis (TB) vaccine and host-directed therapy platforms and models, 2) Blood processing and clinical immunology secondary endpoint and exploratory assays for NIH, VTEU, IDCRC and Biotech-funded trials to evaluate vaccines against SARS-CoV-2 and Mycobacterium tuberculosis 3) Nontuberculous mycobacteria vaccine development and 4) Mycobacteriophages therapy to kill superbugs.

Dr. Coler’s research has contributed to the invention of the M72/AS01e and ID93+GLA-SE – lead TB vaccine candidates. Dr. Coler’s clinical trials include prophylactic and therapeutic vaccines for a variety of infectious diseases including TB, COVID-19, influenza, and schistosomiasis.

Dr. Coler is passionate about training the next generation of researchers, and promoting awareness about Diversity, Equity, and Inclusion.

Outside of the University, Dr. Coler enjoys spending time with her family and friends, cooking, reading, traveling and scuba diving.